Among the 848 ICI-treated patients with advanced melanoma included in the study, 640 patients were treated with anti-PD-1 monotherapy (N = 251 stage 3, N = 389 stage 4) and 208 patients were treated with combination anti-CTLA-4/PD-1 therapy (all stage 4) (Supplementary Figure S1). The gene discussed is PDCD1; the disease is melanoma.